GlassScriptPhysician profile
Pradip Shah
NPI 1437175155
$13,435.87
in general payments reported to CMS, 2019-2025
38 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $1,091 · 2021: $1,854 · 2022: $1,692 · 2023: $1,127 · 2024: $5,268 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,788 · Food and Beverage: $3,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,787.50 |
| Food and Beverage | $3,753.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $3,832.82 | 2024-2025 | Fetroja |
| Viiv Healthcare Company | $1,489.31 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $1,262.48 | 2019-2025 | Veklury, Biktarvy |
| Merck Sharp & Dohme LLC | $780.06 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $758.49 | 2019-2024 | Jardiance |
| Insmed, INC. | $573.20 | 2022-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $571.23 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $567.78 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $499.72 | 2020-2025 | Arexvy |
| Novartis Pharmaceuticals Corporation | $449.19 | 2019-2024 | |
| Janssen Biotech, INC. | $290.41 | 2019-2023 | Symtuza |
| Astrazeneca Pharmaceuticals LP | $249.89 | 2022-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.61 | 2024-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $249.52 | 2019-2021 | |
| Lilly USA, LLC | $215.40 | 2020-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradip Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.